General
Preferred name
toloxatone
Synonyms
MD 69276 ()
Humoryl, Perenum, Umoril, ??ɳͪ ()
Toloxatone (MD69276) ()
Humoryl, Perenum, Umoril ()
Humoryl ()
P&D ID
PD008985
CAS
29218-27-7
Tags
natural product
drug
available
Drug indication
Discovery agent
Drug Status
approved
experimental
Max Phase
4.0
First approval
1984
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA
This medication is a reversible inhibitor of monoamine oxidase type-A (also known as RIMA). ; MAO-A can be found in norepinephrinergic and serotonergic neurons and regulates the metabolism of serotonin and catecholamines, allowing for increased circulation in the synaptic cleft. ; Traditional monoamine oxidase inhibitors irreversibly inhibit monoamine oxidase and therefore, side effects, drug interactions, and food interactions persist as long as 2-3 weeks after discontinuing toloxatone. The elevation of serotonin and norepinephrine levels occurs rapidly after medication administration. However, the therapeutic relief of depressive symptoms requires weeks of daily treatment to observe results. Selective and reversible MAO-A inhibitors are more effective in treating major depression without several of the drug and food interactions associated with traditional monoamine oxidase inhibitors [L1389].;
ROE
Mainly hepatic; 1% of drug is excreted unchanged in the urine [A31957]
TOXICITY
In rare cases, toloxatone toxicity may cause fulminant hepatitis [L1389].; More common adverse effects include dysuria, nausea, constipation, vertigo, and insomnia.; Administration of toloxatone can lead to an increased risk of serotonin syndrome with selective serotonin reuptake inhibitors (SSRI), and tricyclic antidepressants [L1389]. Increased blood pressure can occur with sympathomimetic medication coadministration. One study showed that when combined with meals, elevated doses of toloxatone may contribute to elevated blood pressure in healthy subjects. This pharmacodynamic interaction could be explained by enhanced tyramine bioavailability in the presence of toloxatone. This tyramine in meals and toloxatone is unlikely to occur in patients after long-term administration of the drug at therapeutic dosages [A31955].
DESCRIPTION
Toloxatone is a reversible monoamine oxidase A (MAOA) inhibitor that can be used as an antidepressant.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
15
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMatrix
Enamine BioReference Compounds
MedChem Express Bioactive Compound Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
26
Molecular Weight
207.09
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
1.31
TPSA
49.77
Fraction CSP3
0.36
Chiral centers
1.0
Largest ring
6.0
QED
0.8
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Metabolism
Neuroscience
Neuronal Signaling
Target
MAO-A
MAO-A inhibitor
Monoamine Oxidase
MOA
MAO
Solubility
Soluble in DMF (30 mg/ml), DMSO (30 mg/ml), Ethanol (30 mg/ml)
Source data
